Browsing: Novo

Novo Nordisk filed a lawsuit against Eli Lilly on Tuesday, alleging that advertising campaigns for Lilly’s obesity drug Zepbound and diabetes drug Mounjaro mislead consumers by using outdated clinical data to suggest those treatments are more effective than Novo’s rival injections

Shop TODAY Beauty Awards: 120 Editor-Tested Products That Made the Cut Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement July 21, 202602:08 $1 Billion up for Grabs as Mega Millions and Powerball Prizes Soar 00:37 Now Playing Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement 02:08 UP NEXT Hundreds Gather to…

Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo‘s drugs

Novo Nordisk A/S (ISIN DK0062498333) stock is trading close to its recent record highs, supported by strong revenue and profit growth driven by its GLP-1 diabetes and obesity portfolio and reflecting a rising market capitalization well above EUR 500 billion as of mid 2025 according to public market data. The Danish pharmaceutical group is listed…

Novo Nordisk stock is trading close to record territory, supported by strong demand for its GLP-1 diabetes and obesity treatments and robust recent financial results. The Danish pharmaceutical group Novo Nordisk A/S (ISIN DK0062498333) has reported double digit revenue and operating profit growth in its latest full year and interim figures, underpinned by rapid uptake…

Novo Nordisk stock is trading close to record territory, with investors focusing on how sustained demand for its obesity and diabetes drugs is feeding through into revenue and profit growth for the Danish pharmaceutical group (ISIN DK0062498333). According to the companys most recent quarterly report for Q1 2025, Novo Nordisk reported revenue of DKK 108.0…

Novo Nordisk (ISIN DK0060534915) remains one of the most closely watched large-cap healthcare names in Europe, with its shares linked to diabetes and obesity demand, revenue growth, and operating-profit trends. The current market setting is best read through the company’s latest reported numbers and its main investor relations channel, which still frames the stock around…

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide